Compare GMAB & BBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMAB | BBY |
|---|---|---|
| Founded | 1999 | 1966 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Video Chains |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 15.6B |
| IPO Year | N/A | N/A |
| Metric | GMAB | BBY |
|---|---|---|
| Price | $31.78 | $74.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 19 |
| Target Price | $40.40 | ★ $84.24 |
| AVG Volume (30 Days) | 1.4M | ★ 4.1M |
| Earning Date | 11-06-2025 | 11-25-2025 |
| Dividend Yield | N/A | ★ 5.12% |
| EPS Growth | ★ 132.41 | N/A |
| EPS | ★ 25.10 | 3.02 |
| Revenue | $3,845,670,022.00 | ★ $41,825,000,000.00 |
| Revenue This Year | $24.85 | $1.77 |
| Revenue Next Year | $16.67 | $1.32 |
| P/E Ratio | ★ $12.31 | $24.54 |
| Revenue Growth | ★ 29.57 | N/A |
| 52 Week Low | $17.24 | $54.99 |
| 52 Week High | $33.65 | $91.68 |
| Indicator | GMAB | BBY |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 40.86 |
| Support Level | $31.32 | $74.24 |
| Resistance Level | $32.41 | $83.67 |
| Average True Range (ATR) | 0.64 | 2.59 |
| MACD | 0.11 | -0.30 |
| Stochastic Oscillator | 73.67 | 11.07 |
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.